Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
Figure 2
Kaplan-Meier curves for overall survival (OS) (a) and progression-free survival (PFS) (b) according to ECOG performance status, EGFR-mutation status, grade of rash, sex, number of therapy lines, histology, smoking status and treatment interruption (only in (b)).
